Moleculin Biotech (MBRX) Operating Income (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Operating Income of -$7.5 million for Q4 2025, down 13.4% year-over-year from -$8.7 million in Q4 2024, and down 27.55% quarter-over-quarter from -$5.9 million in Q3 2025.
Moleculin Biotech (MBRX) Operating Income (2016 - 2026) Analysis & Trends
Moleculin Biotech's Operating Income history runs 10 years deep, the most recent figure standing at -$7.5 million for Q4 2025.
- In Q4 2025, Operating Income fell 13.4% year-over-year to -$7.5 million; the TTM figure through Dec 2025 stood at -$25.1 million (up 5.77% YoY), while the FY2025 annual figure was -$25.1 million, up 5.77% from the prior year.
- Operating Income for Q4 2025 stood at -$7.5 million, down from -$5.9 million in the prior quarter.
- The five-year high for Operating Income was -$5.2 million in Q4 2021, with the low at -$9.1 million in Q3 2022.
- The 5-year median for Operating Income is -$6.5 million (2023), against an average of -$6.7 million.
- The sharpest annual moves came in 2021 and 2023: Operating Income tumbled 48.93% in 2021, then soared 34.53% in 2023.
- Moleculin Biotech's Operating Income stood at -$5.2 million in 2021, then plunged by 35.41% to -$7.0 million in 2022, then retreated by 26.55% to -$8.9 million in 2023, then rose by 25.52% to -$6.6 million in 2024, then slipped by 13.4% to -$7.5 million in 2025.
- Business Quant data shows MBRX's Operating Income at -$7.5 million in Q4 2025, -$5.9 million in Q3 2025, and -$5.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 133.12 Mn |
| 10 | Moleculin Biotech | 3.30 Mn | 3.30 Mn | - | -7.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.56 Mn |
| Dec 31, 2025 | -7.53 Mn |
| Sep 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -5.94 Mn |
| Dec 31, 2024 | -6.64 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -6.19 Mn |
| Mar 31, 2024 | -6.68 Mn |
| Dec 31, 2023 | -8.92 Mn |
| Sep 30, 2023 | -5.95 Mn |
| Jun 30, 2023 | -6.41 Mn |
| Mar 31, 2023 | -8.35 Mn |
| Dec 31, 2022 | -7.05 Mn |
| Sep 30, 2022 | -9.08 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Mar 31, 2022 | -7.07 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -6.16 Mn |
| Jun 30, 2021 | -5.52 Mn |